188 related articles for article (PubMed ID: 8013154)
1. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Labrie F; Dupont A; Cusan L; Gomez JL; Diamond P
Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
Labrie F; Dupont A; Cusan L; Bélanger A; Giguère M; Labrie C; Lacourcière Y; Monfette G; Emond J
Prog Clin Biol Res; 1988; 262():11-63. PubMed ID: 3287388
[No Abstract] [Full Text] [Related]
4. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
St-Arnaud R; Lachance R; Dupont A; Labrie F
Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
[TBL] [Abstract][Full Text] [Related]
6. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
7. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
8. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
9. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
[TBL] [Abstract][Full Text] [Related]
10. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
11. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
Pummer K
Semin Oncol; 1991 Oct; 18(5 Suppl 6):26-8. PubMed ID: 1948120
[TBL] [Abstract][Full Text] [Related]
13. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
Labrie F; Dupont A; Cusan L; Gomez J; Diamond P; Koutsilieris M; Suburu R; Fradet Y; Lemay M; Têtu B
Clin Invest Med; 1993 Dec; 16(6):499-509. PubMed ID: 8013155
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy for prostate cancer.
Labrie F
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life among patients with metastatic prostate cancer.
Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
[TBL] [Abstract][Full Text] [Related]
16. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
17. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
[TBL] [Abstract][Full Text] [Related]
19. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo.
Benson RC; Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Dorr FA
Semin Oncol; 1991 Oct; 18(5 Suppl 6):9-12. PubMed ID: 1948121
[TBL] [Abstract][Full Text] [Related]
20. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]